The Wall Street Journal reports that Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. have embarked on a Phase 3 clinical trial to test rebamipide ophthalmic suspension intended to improve dry eye syndrome. Dr. William Boothe looks forward to the results of this trial, as this condition affects a large number of people throughout the United States.
According to the article, “Rebamipide ophthalmic suspension is a novel compound discovered by Otsuka Pharmaceutical and has a new mechanism of action to increase the level of mucin in the tear film covering the conjunctiva and cornea. In January 2012, the drug was launched for the treatment of dry eye syndrome in Japan as Mucosta® ophthalmic suspension UD2%.”
The symptoms associated with dry eye syndrome can vary, but they often manifest as burning, pain, dryness, itching, and the sensation of having something in the eye. Additionally, photophobia may develop. If advanced, the condition can lead to dangerous complications that can damage the surface of the eye, resulting in vision impairment.
Ryo Kubota, MD, PhD, who is the Chairman, President, and CEO of Acucela Inc., states: “Advancing rebamipide ophthalmic suspension into late-stage development is an exciting and important milestone for Acucela and for the patients who suffer from the debilitating effects of dry eye. Today’s announcement is in line with our strategy to develop leading-edge therapies to help patients living with disabling eye diseases around the world. We are excited about the initiation of this important clinical study for rebamipide, as we continue to advance our pipeline of innovative ophthalmology treatments through the clinic.”
Dr. Boothe looks forward to the results of the clinical trial.
“These are the kinds of initiatives that push the medical industry forward,” asserts Dr. Boothe. “By exploring new treatment options and creating innovative new ways to improve conditions like dry eye syndrome, researchers are able to enhance the patient care that we, as practicing doctors, are able to provide to our patients.”
Dr. William Boothe is an ophthalmologist who specializes in corneal conditions. Additionally, he provides general care through his practice, Boothe Eye Care. Dr. William Boothe leads the industry in LASIK laser procedures, as he has performed over 130,000 of them over the course of his career. In fact, Dr. William Boothe holds the record for completing the most IntraLASIK operations in the world. When not operating or treating patients, Dr. William Boothe is teaching at various schools and organizations to pass his knowledge on to other healthcare professionals. As a result, he is able to improve the overall level of care that patients across the country receive. Dr. Boothe is a member of the American Medical Association, Texas Medical Association, International Society of Refractive Surgery, and Texas Ophthalmologic Association.